{"id":22942,"date":"2024-06-11T08:19:31","date_gmt":"2024-06-11T12:19:31","guid":{"rendered":"https:\/\/medicarereport.org\/?p=22942"},"modified":"2024-06-11T08:19:32","modified_gmt":"2024-06-11T12:19:32","slug":"fda-advisors-strongly-back-new-alzheimers-drug-despite-risks-and-limitations","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=22942","title":{"rendered":"FDA advisors strongly back new Alzheimer\u2019s drug, despite risks and limitations"},"content":{"rendered":"\n<p>(By Jon Hamilton for NPR)<\/p>\n\n\n\n<p>Advisors to the Food and Drug Administration have recommended unanimously that the agency approve the Alzheimer\u2019s drug donanemab.<\/p>\n\n\n\n<p>At a meeting Monday, the Peripheral and Central Nervous System Drugs Advisory Committee voted 11-0 that donanemab is effective at slowing down Alzheimer\u2019s in the disease\u2019s early stages and that the drug\u2019s benefits outweigh its risks.  Continue reading <a href=\"https:\/\/www.npr.org\/sections\/shots-health-news\/2024\/06\/10\/g-s1-3818\/fda-advisors-back-alzheimer-drug-donanemab-despite-risks\" data-type=\"link\" data-id=\"https:\/\/www.npr.org\/sections\/shots-health-news\/2024\/06\/10\/g-s1-3818\/fda-advisors-back-alzheimer-drug-donanemab-despite-risks\">here&#8230;<\/a><\/p>\n\n\n\n<p><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"54\" class=\"wp-image-3902\" style=\"width: 150px;\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png\" alt=\"\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png 152w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo-150x55.png 150w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>Notice:<\/strong>\u00a0The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Jon Hamilton for NPR) Advisors to the Food and Drug Administration have recommended unanimously that the agency approve the<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,31,15],"tags":[252,599,76,385,65,94],"class_list":["post-22942","post","type-post","status-publish","format-standard","hentry","category-alzheimersdementia","category-fda","category-part-dprescription-drugs","tag-alzheimers-treatment","tag-donanemab","tag-fda","tag-healthcare-costs","tag-medicare-part-d","tag-older-adults"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/22942","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22942"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/22942\/revisions"}],"predecessor-version":[{"id":22943,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/22942\/revisions\/22943"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22942"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22942"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}